Anakinra versus intramuscular methylprednisolone acetate for gout flares in people with chronic kidney disease (ASGARD): a UK randomised multicentre, double-blind, double-dummy controlled feasibility study with economic, qualitative and safety assessment.

Balasubramaniam G, Almond M, Harnett P, Turner D, Scales J, Zhang J, Moore C, Hayden K, Roddy E, Mallen C, Stack J, Bhagat S, Ng N, Rutherford A, Dasgupta B

Open source

DOI: 10.1136/bmjopen-2025-114454
Published: 2026 Sep 30
Container: BMJ open
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/bmjopen-2025-114454,
  title = {Anakinra versus intramuscular methylprednisolone acetate for gout flares in people with chronic kidney disease (ASGARD): a UK randomised multicentre, double-blind, double-dummy controlled feasibility study with economic, qualitative and safety assessment.},
  author = {Balasubramaniam G and Almond M and Harnett P and Turner D and Scales J and Zhang J and Moore C and Hayden K and Roddy E and Mallen C and Stack J and Bhagat S and Ng N and Rutherford A and Dasgupta B},
  year = {2026},
  journal = {BMJ open},
  doi = {10.1136/bmjopen-2025-114454},
  url = {https://doi.org/10.1136/bmjopen-2025-114454}
}

RIS

TY  - JOUR
TI  - Anakinra versus intramuscular methylprednisolone acetate for gout flares in people with chronic kidney disease (ASGARD): a UK randomised multicentre, double-blind, double-dummy controlled feasibility study with economic, qualitative and safety assessment.
AU  - Balasubramaniam G
AU  - Almond M
AU  - Harnett P
AU  - Turner D
AU  - Scales J
AU  - Zhang J
AU  - Moore C
AU  - Hayden K
AU  - Roddy E
AU  - Mallen C
AU  - Stack J
AU  - Bhagat S
AU  - Ng N
AU  - Rutherford A
AU  - Dasgupta B
PY  - 2026
JO  - BMJ open
DO  - 10.1136/bmjopen-2025-114454
UR  - https://doi.org/10.1136/bmjopen-2025-114454
ER  -

APA

G, B., M, A., P, H., D, T., J, S., J, Z., C, M., K, H., E, R., C, M., J, S., S, B., N, N., A, R., & B, D. (2026). Anakinra versus intramuscular methylprednisolone acetate for gout flares in people with chronic kidney disease (ASGARD): a UK randomised multicentre, double-blind, double-dummy controlled feasibility study with economic, qualitative and safety assessment.. BMJ open. https://doi.org/10.1136/bmjopen-2025-114454

Source records

pubmed · retrieved 2026-11-10T13:35:43.409Z
europe-pmc · retrieved 2026-11-10T13:35:43.468Z
doaj · retrieved 2026-11-10T13:35:43.400Z